vs
ALTISOURCE PORTFOLIO SOLUTIONS S.A.（ASPS）与HERON THERAPEUTICS, INC.（HRTX）财务数据对比。点击上方公司名可切换其他公司
ALTISOURCE PORTFOLIO SOLUTIONS S.A.的季度营收约是HERON THERAPEUTICS, INC.的1.0倍（$42.3M vs $40.6M），HERON THERAPEUTICS, INC.净利率更高（-7.3% vs -16.8%，领先9.6%），ALTISOURCE PORTFOLIO SOLUTIONS S.A.同比增速更快（3.2% vs -0.5%），过去两年HERON THERAPEUTICS, INC.的营收复合增速更高（8.2% vs 3.6%）
Altisource Portfolio Solutions S.A.是面向抵押贷款、房地产及消费金融领域的全球服务商，为贷款机构、服务商、投资者等市场参与者提供技术、数据与运营解决方案，优化资产管理、房产交易等业务流程，提升客户运营效率。
安提贝制药是一家总部位于多伦多的制药企业，由曾参与创立全球首个气态介质药物开发企业NicOx的约翰·L·华莱士创立于2009年。该企业专注于依托气态介质技术研发缓解疼痛与炎症的药物，2013年在多伦多风险交易所挂牌，2015年收购再生医学领域经销商Citagenix，2020年11月转板多伦多证券交易所。
ASPS vs HRTX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $42.3M | $40.6M |
| 净利润 | $-7.1M | $-3.0M |
| 毛利率 | 26.5% | 72.6% |
| 营业利润率 | -15.5% | 0.1% |
| 净利率 | -16.8% | -7.3% |
| 营收同比 | 3.2% | -0.5% |
| 净利润同比 | 18.2% | -180.6% |
| 每股收益（稀释后） | $-1.02 | $-0.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $42.3M | $40.6M | ||
| Q3 25 | $41.9M | $38.2M | ||
| Q2 25 | $43.3M | $37.2M | ||
| Q1 25 | $43.4M | $38.9M | ||
| Q4 24 | $41.0M | $40.8M | ||
| Q3 24 | $40.5M | $32.8M | ||
| Q2 24 | $39.1M | $36.0M | ||
| Q1 24 | $39.5M | $34.7M |
| Q4 25 | $-7.1M | $-3.0M | ||
| Q3 25 | $-2.3M | $-17.5M | ||
| Q2 25 | $16.7M | $-2.4M | ||
| Q1 25 | $-5.3M | $2.6M | ||
| Q4 24 | $-8.7M | $3.7M | ||
| Q3 24 | $-9.3M | $-4.8M | ||
| Q2 24 | $-8.3M | $-9.2M | ||
| Q1 24 | $-9.2M | $-3.2M |
| Q4 25 | 26.5% | 72.6% | ||
| Q3 25 | 27.1% | 68.8% | ||
| Q2 25 | 30.1% | 73.5% | ||
| Q1 25 | 30.7% | 78.3% | ||
| Q4 24 | 30.3% | 74.9% | ||
| Q3 24 | 29.8% | 71.2% | ||
| Q2 24 | 32.5% | 70.8% | ||
| Q1 24 | 31.2% | 75.6% |
| Q4 25 | -15.5% | 0.1% | ||
| Q3 25 | 1.2% | -10.7% | ||
| Q2 25 | 7.5% | -4.4% | ||
| Q1 25 | 7.5% | 8.1% | ||
| Q4 24 | 1.4% | 10.2% | ||
| Q3 24 | 2.7% | -13.6% | ||
| Q2 24 | 5.3% | -17.9% | ||
| Q1 24 | -1.4% | -13.8% |
| Q4 25 | -16.8% | -7.3% | ||
| Q3 25 | -5.5% | -45.8% | ||
| Q2 25 | 38.5% | -6.4% | ||
| Q1 25 | -12.1% | 6.8% | ||
| Q4 24 | -21.3% | 9.0% | ||
| Q3 24 | -23.0% | -14.8% | ||
| Q2 24 | -21.1% | -25.6% | ||
| Q1 24 | -23.2% | -9.1% |
| Q4 25 | $-1.02 | $-0.01 | ||
| Q3 25 | $-0.22 | $-0.10 | ||
| Q2 25 | $1.48 | $-0.02 | ||
| Q1 25 | $-0.09 | $0.01 | ||
| Q4 24 | $-4.72 | $0.02 | ||
| Q3 24 | $-2.61 | $-0.03 | ||
| Q2 24 | $-2.33 | $-0.06 | ||
| Q1 24 | $-0.33 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $26.6M | $28.6M |
| 总债务越低越好 | $191.1M | — |
| 股东权益账面价值 | $-110.2M | $14.3M |
| 总资产 | $139.8M | $255.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $26.6M | $28.6M | ||
| Q3 25 | $28.6M | $43.1M | ||
| Q2 25 | $30.0M | $16.5M | ||
| Q1 25 | $30.8M | $19.3M | ||
| Q4 24 | $29.8M | $25.8M | ||
| Q3 24 | $28.3M | $25.7M | ||
| Q2 24 | $29.7M | $18.4M | ||
| Q1 24 | $29.6M | $20.4M |
| Q4 25 | $191.1M | — | ||
| Q3 25 | $192.5M | — | ||
| Q2 25 | $193.9M | — | ||
| Q1 25 | $195.0M | — | ||
| Q4 24 | $230.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-110.2M | $14.3M | ||
| Q3 25 | $-104.2M | $14.9M | ||
| Q2 25 | $-102.7M | $-27.3M | ||
| Q1 25 | $-119.8M | $-28.5M | ||
| Q4 24 | $-157.4M | $-33.7M | ||
| Q3 24 | $-149.4M | $-40.0M | ||
| Q2 24 | $-140.8M | $-37.9M | ||
| Q1 24 | $-133.3M | $-33.8M |
| Q4 25 | $139.8M | $255.9M | ||
| Q3 25 | $139.9M | $248.9M | ||
| Q2 25 | $142.9M | $232.1M | ||
| Q1 25 | $145.7M | $235.8M | ||
| Q4 24 | $143.6M | $233.1M | ||
| Q3 24 | $144.5M | $220.8M | ||
| Q2 24 | $146.6M | $218.1M | ||
| Q1 24 | $148.9M | $217.9M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-505.0K | $-9.2M |
| 自由现金流经营现金流 - 资本支出 | $-525.0K | — |
| 自由现金流率自由现金流/营收 | -1.2% | — |
| 资本支出强度资本支出/营收 | 0.0% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-5.1M | — |
8季度趋势，按日历期对齐
| Q4 25 | $-505.0K | $-9.2M | ||
| Q3 25 | $718.0K | $1.3M | ||
| Q2 25 | $-306.0K | $-10.9M | ||
| Q1 25 | $-5.0M | $-8.9M | ||
| Q4 24 | $-1.4M | $-11.8M | ||
| Q3 24 | $-1.6M | $3.4M | ||
| Q2 24 | $180.0K | $-4.6M | ||
| Q1 24 | $-2.2M | $-9.5M |
| Q4 25 | $-525.0K | — | ||
| Q3 25 | $697.0K | — | ||
| Q2 25 | $-309.0K | $-11.1M | ||
| Q1 25 | $-5.0M | $-9.0M | ||
| Q4 24 | $-1.4M | — | ||
| Q3 24 | — | $2.9M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -1.2% | — | ||
| Q3 25 | 1.7% | — | ||
| Q2 25 | -0.7% | -29.8% | ||
| Q1 25 | -11.5% | -23.1% | ||
| Q4 24 | -3.4% | — | ||
| Q3 24 | — | 9.0% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 0.0% | 0.0% | ||
| Q3 25 | 0.1% | 0.0% | ||
| Q2 25 | 0.0% | 0.6% | ||
| Q1 25 | 0.1% | 0.3% | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | 1.3% | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.02× | — | ||
| Q1 25 | — | -3.37× | ||
| Q4 24 | — | -3.22× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASPS
| Services | $39.9M | 94% |
| Revenue Relatedto Technology Platformsand Professional Services | $2.4M | 6% |
HRTX
| CINVANTI | $22.9M | 56% |
| ZYNRELEF | $12.5M | 31% |
| Aponvie | $3.8M | 9% |
| SUSTOL | $1.3M | 3% |
